Longevity and Anti-senescence Therapy Market By Therapy (Senolytic Drug Therapy, Gene Therapy, Immunotherapy), By Application (Cancer, Others), By End user (Hospital, Medical Service Institution): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global longevity and anti-senescence therapy market was valued at $25,087.3 million in 2020, and is projected to reach $44,234.8 million by 2030, registering a CAGR of 6.1% from 2021 to 2030.
Aging is marked by a progressive loss of physiological integrity and function over time. Aging epigenetics refers to the changes in gene expression that occur naturally during a lifespan of the organism without changing the DNA sequence. Several enzymes are involved in chromatin epigenetics, which result in changes in DNA methylation and histone methylation/acetylation processes. Chromatin appears to be more active during ageing, resulting in more relaxed global gene expression with an overall decrease in DNA methylation. Senescent cells are linked with many age-related diseases such as cataract, glaucoma, neurodegenerative diseases (Alzheimer and Parkinson), cardiovascular diseases (CVD, atherosclerosis, and hypertension), idiopathic pulmonary fibrosis (IPF), diabetes type II, sarcopenia, osteoarthritis, osteoporosis, chronic obstructive pulmonary disease (COPD), and certain types of tumors.
Increase in prevalence of chronic diseases, rise in awareness about anti-aging products, and advancements in AI driven medical technology drive the growth of the market. Moreover, increase in geriatric population and increase in demand for personalized, precise, preventive, and participatory aging treatments contribute toward the growth of the market. However, dearth of skilled professionals and loss of tissue-repair capacity are the major barriers that hinder the growth of the market. Conversely, increase in demand for cell-based assays in R&D are expected to offer lucrative growth opportunities for market during the forecast period.
The global longevity and anti-senescence therapy market is segmented on the basis of therapy, application, end user and region. Depending on therapy, it is categorized into senolytic drug therapy, gene therapy and immunotherapy. On the basis of application, the market is classified as cancer and others. According to end user, it is classified into hospitals and medical service institution. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AgeX Therapeutics Inc., Bristol-Myers Squibb Company, Calico Life Sciences LLC, CohBar, Inc., Life Biosciences, Inc., Merck & Co. Inc., Oisin Biotechnologies, Pfizer, Inc., T.A. Sciences, Inc., Unity Biotechnology, Inc.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2030, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the longevity and anti-senescence therapy market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By THERAPY
Senolytic Drug Therapy
Gene Therapy
Immunotherapy
By APPLICATION
Cancer
Others
By END USER
Hospitals
Medical Service Institution
By REGION
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Ital
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
AgeX Therapeutics, Inc.
Bristol-Myers Squibb Company
Calico Life Sciences LLC
CohBar, Inc.
Life Biosciences, Inc.
Merck & Co. Inc.
Oisin Biotechnologies
Pfizer, Inc.
T.A. Sciences, Inc.
Unity Biotechnology, Inc.
Key Market Segments
By Therapy
Senolytic Drug Therapy
Gene Therapy
Immunotherapy
By Application
Cancer
Others
By End user
Hospital
Medical Service Institution
By Region
LAMEA
Brazil
Turkey
South Africa
Rest of LAMEA
North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Rest of Asia-Pacific
Key Market Players
AgeX Therapeutics, Inc.
Bristol-Myers Squibb Company
Calico Life Sciences LLC
CohBar, Inc.
Life Biosciences, Inc.
Merck & Co., Inc.
Oisin Biotechnologies
Pfizer Inc.
T.A. Sciences, Inc.
Unity Biotechnology, Inc.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Senolytic Drug Therapy
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Gene Therapy
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Immunotherapy
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Cancer
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Others
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Medical Service Institution
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 LAMEA
- 7.2.1 Key trends and opportunities
- 7.2.2 LAMEA Market size and forecast, by Therapy
- 7.2.3 LAMEA Market size and forecast, by Application
- 7.2.4 LAMEA Market size and forecast, by End user
- 7.2.5 LAMEA Market size and forecast, by country
- 7.2.5.1 Brazil
- 7.2.5.1.1 Market size and forecast, by Therapy
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by End user
- 7.2.5.2 Turkey
- 7.2.5.2.1 Market size and forecast, by Therapy
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by End user
- 7.2.5.3 South Africa
- 7.2.5.3.1 Market size and forecast, by Therapy
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by End user
- 7.2.5.4 Rest of LAMEA
- 7.2.5.4.1 Market size and forecast, by Therapy
- 7.2.5.4.2 Market size and forecast, by Application
- 7.2.5.4.3 Market size and forecast, by End user
- 7.3 North America
- 7.3.1 Key trends and opportunities
- 7.3.2 North America Market size and forecast, by Therapy
- 7.3.3 North America Market size and forecast, by Application
- 7.3.4 North America Market size and forecast, by End user
- 7.3.5 North America Market size and forecast, by country
- 7.3.5.1 U.S.
- 7.3.5.1.1 Market size and forecast, by Therapy
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by End user
- 7.3.5.2 Canada
- 7.3.5.2.1 Market size and forecast, by Therapy
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by End user
- 7.3.5.3 Mexico
- 7.3.5.3.1 Market size and forecast, by Therapy
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by End user
- 7.4 Europe
- 7.4.1 Key trends and opportunities
- 7.4.2 Europe Market size and forecast, by Therapy
- 7.4.3 Europe Market size and forecast, by Application
- 7.4.4 Europe Market size and forecast, by End user
- 7.4.5 Europe Market size and forecast, by country
- 7.4.5.1 Germany
- 7.4.5.1.1 Market size and forecast, by Therapy
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by End user
- 7.4.5.2 France
- 7.4.5.2.1 Market size and forecast, by Therapy
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by End user
- 7.4.5.3 United Kingdom
- 7.4.5.3.1 Market size and forecast, by Therapy
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by End user
- 7.4.5.4 Italy
- 7.4.5.4.1 Market size and forecast, by Therapy
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by End user
- 7.4.5.5 Rest of Europe
- 7.4.5.5.1 Market size and forecast, by Therapy
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by End user
- 7.5 Asia-Pacific
- 7.5.1 Key trends and opportunities
- 7.5.2 Asia-Pacific Market size and forecast, by Therapy
- 7.5.3 Asia-Pacific Market size and forecast, by Application
- 7.5.4 Asia-Pacific Market size and forecast, by End user
- 7.5.5 Asia-Pacific Market size and forecast, by country
- 7.5.5.1 Japan
- 7.5.5.1.1 Market size and forecast, by Therapy
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by End user
- 7.5.5.2 China
- 7.5.5.2.1 Market size and forecast, by Therapy
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by End user
- 7.5.5.3 Australia
- 7.5.5.3.1 Market size and forecast, by Therapy
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by End user
- 7.5.5.4 India
- 7.5.5.4.1 Market size and forecast, by Therapy
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by End user
- 7.5.5.5 Rest of Asia-Pacific
- 7.5.5.5.1 Market size and forecast, by Therapy
- 7.5.5.5.2 Market size and forecast, by Application
- 7.5.5.5.3 Market size and forecast, by End user
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 AgeX Therapeutics, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Bristol-Myers Squibb Company
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Calico Life Sciences LLC
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 CohBar, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Life Biosciences, Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Merck & Co., Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Oisin Biotechnologies
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Pfizer Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 T.A. Sciences, Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Unity Biotechnology, Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 2. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR SENOLYTIC DRUG THERAPY, BY REGION , 2020-2030,($MILLION)
- TABLE 3. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET SENOLYTIC DRUG THERAPY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR GENE THERAPY, BY REGION , 2020-2030,($MILLION)
- TABLE 5. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET GENE THERAPY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR IMMUNOTHERAPY, BY REGION , 2020-2030,($MILLION)
- TABLE 7. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET IMMUNOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
- TABLE 8. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 9. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR CANCER, BY REGION , 2020-2030,($MILLION)
- TABLE 10. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET CANCER BY COUNTRY, 2020-2030,($MILLION)
- TABLE 11. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
- TABLE 12. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. GLOBAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 14. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR HOSPITAL, BY REGION , 2020-2030,($MILLION)
- TABLE 15. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET HOSPITAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 16. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET REVENUE, FOR MEDICAL SERVICE INSTITUTION, BY REGION , 2020-2030,($MILLION)
- TABLE 17. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET MEDICAL SERVICE INSTITUTION BY COUNTRY, 2020-2030,($MILLION)
- TABLE 18. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 19. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 20. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 21. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 22. LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 23. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 24. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 25. BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 26. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 27. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 28. TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 29. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 30. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 31. SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 32. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 33. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 34. REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 35. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 36. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 37. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 38. NORTH AMERICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 39. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 40. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 41. U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 42. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 43. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 44. CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 45. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 46. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 47. MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 48. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 49. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 50. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 51. EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 52. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 53. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 54. GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 55. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 56. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 57. FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 58. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 59. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 60. UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 61. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 62. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 63. ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 64. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 65. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 66. REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 67. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
- TABLE 68. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
- TABLE 69. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
- TABLE 70. ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 71. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 72. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 73. JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 74. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 75. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 76. CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 77. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 78. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 79. AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 80. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 81. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 82. INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 83. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
- TABLE 84. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY END USER 2020-2030,($MILLION)
- TABLE 86.AGEX THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 87.AGEX THERAPEUTICS, INC.: OPERATING SEGMENTS
- TABLE 88.AGEX THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 89.AGEX THERAPEUTICS, INC.: NET SALES,
- TABLE 90.AGEX THERAPEUTICS, INC.: KEY STRATERGIES
- TABLE 91.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 92.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
- TABLE 93.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 94.BRISTOL-MYERS SQUIBB COMPANY: NET SALES,
- TABLE 95.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
- TABLE 96.CALICO LIFE SCIENCES LLC: COMPANY SNAPSHOT
- TABLE 97.CALICO LIFE SCIENCES LLC: OPERATING SEGMENTS
- TABLE 98.CALICO LIFE SCIENCES LLC: PRODUCT PORTFOLIO
- TABLE 99.CALICO LIFE SCIENCES LLC: NET SALES,
- TABLE 100.CALICO LIFE SCIENCES LLC: KEY STRATERGIES
- TABLE 101.COHBAR, INC.: COMPANY SNAPSHOT
- TABLE 102.COHBAR, INC.: OPERATING SEGMENTS
- TABLE 103.COHBAR, INC.: PRODUCT PORTFOLIO
- TABLE 104.COHBAR, INC.: NET SALES,
- TABLE 105.COHBAR, INC.: KEY STRATERGIES
- TABLE 106.LIFE BIOSCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 107.LIFE BIOSCIENCES, INC.: OPERATING SEGMENTS
- TABLE 108.LIFE BIOSCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 109.LIFE BIOSCIENCES, INC.: NET SALES,
- TABLE 110.LIFE BIOSCIENCES, INC.: KEY STRATERGIES
- TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
- TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 114.MERCK & CO., INC.: NET SALES,
- TABLE 115.MERCK & CO., INC.: KEY STRATERGIES
- TABLE 116.OISIN BIOTECHNOLOGIES: COMPANY SNAPSHOT
- TABLE 117.OISIN BIOTECHNOLOGIES: OPERATING SEGMENTS
- TABLE 118.OISIN BIOTECHNOLOGIES: PRODUCT PORTFOLIO
- TABLE 119.OISIN BIOTECHNOLOGIES: NET SALES,
- TABLE 120.OISIN BIOTECHNOLOGIES: KEY STRATERGIES
- TABLE 121.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 122.PFIZER INC.: OPERATING SEGMENTS
- TABLE 123.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 124.PFIZER INC.: NET SALES,
- TABLE 125.PFIZER INC.: KEY STRATERGIES
- TABLE 126.T.A. SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 127.T.A. SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 128.T.A. SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 129.T.A. SCIENCES, INC.: NET SALES,
- TABLE 130.T.A. SCIENCES, INC.: KEY STRATERGIES
- TABLE 131.UNITY BIOTECHNOLOGY, INC.: COMPANY SNAPSHOT
- TABLE 132.UNITY BIOTECHNOLOGY, INC.: OPERATING SEGMENTS
- TABLE 133.UNITY BIOTECHNOLOGY, INC.: PRODUCT PORTFOLIO
- TABLE 134.UNITY BIOTECHNOLOGY, INC.: NET SALES,
- TABLE 135.UNITY BIOTECHNOLOGY, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET SEGMENTATION
- FIGURE 2.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030
- FIGURE 3.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY THERAPY,2020(%)
- FIGURE 12.COMPARATIVE SHARE ANALYSIS OF SENOLYTIC DRUG THERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENE THERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 15.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY APPLICATION,2020(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CANCER LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 18.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,BY END USER,2020(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF MEDICAL SERVICE INSTITUTION LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030(%)
- FIGURE 21.LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET BY REGION,2020
- FIGURE 22.BRAZIL LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 23.TURKEY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 24.SOUTH AFRICA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 25.REST OF LAMEA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 26.U.S. LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 27.CANADA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 28.MEXICO LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 29.GERMANY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 30.FRANCE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 31.UNITED KINGDOM LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 32.ITALY LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 33.REST OF EUROPE LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 34.JAPAN LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 35.CHINA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 36.AUSTRALIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 37.INDIA LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 38.REST OF ASIA-PACIFIC LONGEVITY AND ANTI-SENESCENCE THERAPY MARKET,2020-2030($MILLION)
- FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 43.COMPETITIVE DASHBOARD
- FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 45.AGEX THERAPEUTICS, INC..: NET SALES ,($MILLION)
- FIGURE 46.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ,($MILLION)
- FIGURE 47.CALICO LIFE SCIENCES LLC.: NET SALES ,($MILLION)
- FIGURE 48.COHBAR, INC..: NET SALES ,($MILLION)
- FIGURE 49.LIFE BIOSCIENCES, INC..: NET SALES ,($MILLION)
- FIGURE 50.MERCK & CO., INC..: NET SALES ,($MILLION)
- FIGURE 51.OISIN BIOTECHNOLOGIES.: NET SALES ,($MILLION)
- FIGURE 52.PFIZER INC..: NET SALES ,($MILLION)
- FIGURE 53.T.A. SCIENCES, INC..: NET SALES ,($MILLION)
- FIGURE 54.UNITY BIOTECHNOLOGY, INC..: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook